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MaOBJECTIVES This study sought to report the results of a prospective randomized controlled trial comparing paclitaxel-
coated balloons (PCB) versus drug-eluting stents (DES) in long infrapopliteal lesions.
BACKGROUND DES have an established role in the treatment of short infrapopliteal lesions, whereas there is
increasing evidence for the use of PCB in longer below-the-knee lesions.
METHODS Inclusion criteria were patients with Rutherford classes 3 to 6 and angiographically documented infrapo-
pliteal disease with a minimum lesion length of 70 mm. The primary endpoint was target lesion restenosis >50%
assessed by digital angiography at 6 months. Secondary endpoints included immediate post-procedure stenosis and
target lesion revascularization.
RESULTS Fifty patients were randomized to undergo infrapopliteal PCB angioplasty (25 arteries in 25 limbs; PCB group)
or primary DES placement (30 arteries in 27 limbs; DES group). Immediate residual post-procedure stenosis was signif-
icantly lower in DES (9.6  2.2% vs. 24.8  3.5% in PCB; p < 0.0001). At 6 months, 5 patients died (2 in PCB vs. 3 in
DES; p ¼ 1.00) and 3 suffered a major amputation (1 in PCB vs. 2 in DES; p ¼ 1.00). In total, 44 angiograms were
evaluable with quantitative vessel analysis. Binary (>50%) angiographic restenosis rate was signiﬁcantly lower in DES
(7 of 25 [28%] vs. 11 of 19 [57.9%] in PCB; p ¼ 0.0457). There were no signiﬁcant differences with regard to target lesion
revascularization (2 of 26 [7.7%] in DES vs. 3 of 22 [13.6%] in PCB; p ¼ 0.65). Positive vessel wall remodeling was
observed in 3 cases in the PCB arm (3 of 19 [(15.8%)] vs. 0 of 19 [0%] in DES; p ¼ 0.07).
CONCLUSIONS Compared with PCB in long infrapopliteal lesions, DES are related with signiﬁcantly lower residual
immediate post-procedure stenosis and have shown signiﬁcantly reduced vessel restenosis at 6 months. PCB may produce
positive vessel remodeling. (Infrapopliteal Drug-Eluting Angioplasty Versus Stenting [IDEAS-I]; NCT01517997) (J Am Coll
Cardiol Intv 2014;7:1048–56) © 2014 by the American College of Cardiology Foundation.m the *Interventional Radiology Department, Patras University Hospital, Patras, Greece; and the yInterventional Radiology
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AB BR EV I A T I O N S
AND ACRONYM S
CLI = critical limb ischemia
CTO = chronic total
occlusion(s)
DES = drug-eluting stent(s)
IQR = interquartile range(s)
ITT = intention-to-treat
LLL = late lumen loss
NIH = neointimal hyperplasia
PCB = paclitaxel-coated
balloon
QVA = quantitative vessel
analysis
TLR = target lesion
revascularization
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1049E ndovascular treatment is increasingly beingused as the preferred method of revascul-arization in patients with infrapopliteal
arterial disease suffering from critical limb ischemia
(CLI). Compared with surgical bypass, which can be
technically challenging or not offered at all because
of underlying comorbidities of CLI patients, angio-
plasty of the crural arteries is able to achieve multi-
vessel recanalization to the foot in a safer and less
invasive way (1–3).
Traditional plain balloon angioplasty has long been
the gold standard endovascular therapy in the infra-
popliteal ﬁeld, accompanied by bare-metal stents as a
bailout choice (4,5). Nearly a decade ago, certain in-
vestigators foresaw the advantages of using drug-
eluting stents (DES) in the infrapopliteal region (6–
9). Since then, 3 multicenter randomized controlled
trials and a meta-analysis have conﬁrmed the supe-
riority of DES in terms of inhibiting restenosis,
reducing target lesion revascularization (TLR, and
improving event-free survival, thereby providing
level IA evidence for their use in short infrapopliteal
lesions (10–13).SEE PAGE 1057On the other hand, paclitaxel-coated balloons (PCB)
have already been shown to have superior results with
less vascular restenosis and fewer TLR events than
with plain balloon angioplasty when used in the su-
perﬁcial femoral artery and in failing arteriovenous
ﬁstulas (14,15). Recently, a single-arm and 2 random-
ized controlled trials provided evidence about
improved outcomes with PCB in the treatment of
infrapopliteal lesions, at 3, 6, and 12months, compared
with percutaneous transluminal angioplasty (16–18).
CLI cases, especially diabetic ones, are typically
characterized by long diffuse atherosclerotic lesions
in about one-half of the cases (19). To our knowledge,
there is only 1 single-arm study testing plain balloon
angioplasty in long infrapopliteal lesions, and evi-
dence on the effectiveness of DES in long these
lesions is also very scarce (20,21). On the other hand,
the 2 randomized controlled trials reported applica-
tion of PCB in relatively longer lesions. This trial was
designed to explore the effectiveness of PCB versus
DES speciﬁcally for the treatment of long infrapopli-
teal lesions that are more representative of routine
practice in the treatment of CLI.
METHODS
STUDY DESIGN. The IDEAS (Infrapopliteal Drug-
Eluting Angioplasty Versus Stenting) trial was
designed to be a single-center randomized (1:1)controlled trial comparing PCB versus DES in
long infrapopliteal lesions for the treatment
of CLI. It was hypothesized that the 2
competing drug technologies would produce
similar inhibition of neointimal hyperplasia
(NIH); in other words, the null hypothesis
was set at equivalence. The expected angio-
graphic restenosis rate >50% at 6 months was
estimated at 10% for both groups and the
study was powered to exclude a difference
between the 2 treatments of >25% (a ¼ 0.05
and statistical power set at 0.80). The number
of patients required in each treatment arm
was calculated to be 25. No allowance was
made for dropouts. One-to-one randomiza-
tion was computer generated and the method
of sealed envelopes was used. The hospital’s
ethical and scientiﬁc committee approved the proto-
col. Written informed consent was acquired from all
recruited subjects. The study was announced on a
public database (NCT01517997) and was performed
within standards of care without any ﬁnancial sup-
port from industry or research grants.
PATIENT POPULATIONS. From December 1, 2011 to
January 1st 2013, 73 patients were referred to our
department for percutaneous revascularization of
the infrapopliteal vessels due to intermittent clau-
dication or CLI. After screening for potential
enrollment in the trial, 23 patients were excluded in
total (13 patients did not fulﬁll the inclusion criteria;
8 patients suffered from distal below-the-ankle dis-
ease; and 2 patients did not consent to be included
in the study). Overall, 50 patients met the inclusion
criteria, provided a signed informed consent form
and were randomized to undergo either PCB angio-
plasty (PCB group) or DES placement (DES group)
for the treatment of long infrapopliteal lesions (>70
mm in length, maximum of 2 arteries per limb)
(Figure 1). In order to be included in the trial, pa-
tients had to suffer from severe leg ischemia
(Rutherford classes 3- to 6) and to have $1 angio-
graphically documented infrapopliteal lesion of >70
mm in length. On the other hand, distal arterial
occlusive disease compromising below-the-ankle
runoff of the target vessel to be treated (e.g.,
blocked dorsalis pedis in case of anterior tibial ar-
tery treatment or occluded plantar arteries in case of
posterior tibial artery treatment) was the most
important exclusion criterion (Table 1). Inﬂow ilio-
femoral occlusive disease was treated as necessary.
BALLOON AND STENT DEVICES. The PCB under
investigation was the IN.PACT Amphirion (Medtronic,
Brescia, Italy), which was available in sizes with 3 to
FIGURE 1 Flowchart of the IDEAS Study
Flowchart shows the overall number of subjects recruited and the number of subjects lost
to follow-up or missing because of death or major amputation up to 6 months. DES ¼
drug-eluting stent(s); IDEAS ¼ Infrapopliteal Drug-Eluting Angioplasty Versus Stenting;
PCB ¼ paclitaxel-coated balloon.
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10504 mm diameters and 40 to 120 mm lengths. DES
used included zotarolimus-eluting (Resolute stent,
Medtronic, Brescia, Italy; diameter: 3 to 4 mm,
length: #30 mm), sirolimus-eluting (Cypher stent,
Cordis, Bridgewater, New Jersey; diameter: 3 to
3.5 mm, length: #33 mm), and the everolimus-elutingTABLE 1 Inclusion and Exclusion Criteria
Inclusion criteria
Angiographically documented infrapopliteal arterial occlusive
disease
Rutherford classiﬁcation $3
Single lesion $70 mm (maximum 2 arteries)
Life expectancy $1 yr
Age 18 to 90 yrs
Exclusion criteria
Comorbidities excluding the patient from angioplasty procedure
Allergic reaction to contrast media
Known hypersensitivity to the devices’ drug agents
Below-the-ankle arterial occlusive disease
Known contraindication to aspirin and/or clopidogrelstents (Promus stent, Boston Scientiﬁc, Natick,
Massachusetts; diameter: 3 to 4 mm, length: #38 mm)
according to department’s availability and were
applied as a primary treatment (balloon pre-dilation
as necessary).
PROCEDURE. All procedures were performed with an
antegrade access after puncturing the common
femoral artery under ultrasound guidance and
local anesthetic with lignocaine 1%. A 6-F sheath was
inserted and 5,000 IU of heparin were administered.
An angiogram was obtained and the target lesion
length was measured with the help of a radiopaque
ruler. Lesions were crossed with 0.014-inch to 0.018-
inch guidewires and the appropriate device was
chosen. Pre-dilation was performed in the case of
tight stenosis or after an occlusive lesion was crossed
in both groups. After the device was deployed (DES)
or inﬂated (PCB), a second angiogram was performed.
In the case of residual stenosis, a further prolonged
dilation was performed in both groups and a ﬁnal
angiogram was acquired.
In the PCB group, the inﬂation time was 1 min as
recommended in the instructions for use. Devices
used were 5 mm longer than the actual measured
lesion on each side. In the case where >1 balloon was
needed, an overlap subject to visual estimation
occurred. In the DES group, inﬂation time was 20 se
and devices were deployed in a length matching that
of the actual lesion. The minimum amount of over-
lapping possible was applied with the help of
magniﬁed images. Patients were prescribed on dual
antiplatelet therapy for 6 months. Clinical follow-up
was scheduled at 1 and 6 months and a digital sub-
traction angiography was performed at the 6-month
time point for quantitative vessel analysis (QVA)
purposes.
STUDY ENDPOINTS. Primary study endpoint was
angiographic restenosis >50% (binary) of the target
lesion deﬁned as >50% restenosis of the treated part
of the vessel as measured by QVA. Binary restenosis
was chosen as a primary endpoint of this trial as both
technologies compared are local drug delivery tech-
nologies and an antirestenotic effect (NIH inhibition)
was anticipated.
Secondary endpoints included technical success
deﬁned as the absence of ﬂow-limiting dissection and
no signiﬁcant residual stenosis by visual estimate in
both groups. Further secondary outcome measures
included the following: immediate post-procedure
stenosis; late lumen loss (LLL) as a quantitative
endpoint of NIH deﬁned as the difference between the
minimal lumen diameter immediately after stenting
or PCB angioplasty and the minimal lumen diameter at
TABLE 2 Baseline Demographics and Lesion Characteristics
DES Group PCB Group p Value
Patients 25 25
Male 18/25 (72) 20/25 (80) 0.51
Age, yrs 75.3  8.0 67.6  11.3 0.03
Diabetes 16/25 (64) 19/25 (76) 0.35
Smoking 6/25 (24) 9/25 (36) 0.65
Hypertension 11/25 (44) 14/25 (56) 0.40
Hyperlipidemia 13/25 (52) 10/25 (40) 0.39
Coronary artery disease 8/25 (32) 6/25 (24) 0.53
Chronic kidney disease 8/25 (32) 11/25 (44) 0.38
Rutherford class 4.5 (4, 5) 4.5 (3, 5) 0.69
Inﬂow iliofemoral disease 16/25 (72) 15/25 (60) 0.77
Baseline lesion length, mm 127  46.5 148  56.7 0.14
Chronic total occlusions 7/30 (23) 3/25 (12) 0.31
Baseline stenosis, % 86.8  10.1 85.3  8.9 0.58
Baseline wounds 12/25 (48) 12/25 (48) 1.00
Target vessels
Anterior tibial artery 15/30 (50) 13/25 (52) 0.88
Posterior tibial artery 8/30 (27) 6/25 (24) 0.82
Peroneal artery 7/30 (23) 6/25 (24) 0.94
Severe calciﬁcations 15/30 (50) 11/25 (44) 0.64
Values are n, n/N (%), mean  SD, or median (interquartile range).
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10516-month follow-up; cases of angiographically proven
total vessel occlusion; any clinically driven TLR; major
amputations (above-ankle, planned and unplanned);
Rutherford class improvement; and wound healing of
any baseline tissue loss (classiﬁed as complete, partial,
or stable wounds). Investigators also included in their
QVA analysis the immediate post-procedure residual
stenosis as a surrogate endpoint of immediate device
efﬁcacy. To further investigate the pattern of reste-
nosis and NIH development, the analysis extended to
include the length of the restenosed vascular segment
at 6 months (deﬁned as the length of restenosis >50%
of the previously treated lesion; in centimeters) as well
as any positive vessel remodeling (suggested by a
negative LLL).
STATISTICAL ANALYSIS. All outcomes were re-
ported and analyzed on an intention-to-treat (ITT)
basis. Discrete variables were expressed as counts
(percentages), and continuous variables were given
as medians (interquartile ranges [IQR]) or as mean 
SD if they passed the Kolmogorov-Smirnov goodness-
of-ﬁt normality test. The unpaired Student t test was
used to test normally distributed continuous vari-
ables; the Mann-Whitney U test was used for quali-
tative variables and for nonparametric continuous
variables. Comparison of proportions was done by
testing the null hypothesis that the proportions were
equal, and the chi-square test was applied in case of
cumulative analysis. Fisher exact test has been
applied where appropriate. The threshold of statis-
tical signiﬁcance was set at p < 0.05. Statistical
analysis was performed with the GraphPad Prism
statistical software package (version 5, GraphPad
Software, La Jolla, California).TABLE 3 Angiographic and Clinical Outcomes: QVA and
Outcome Measures at 6 Months (ITT Analysis)
DES Group PCB Group p Value
QVA analysis
Post-procedure
stenosis, %
9.6  2.2 24.8  3.5 <0.0001
6-month vessel
stenosis, %
50.6  6.6 54.3  8.1 0.73
Late lumen loss, mm 1.35  0.2 1.15  0.3 0.62
Length of >50%
restenosis, cm
3.6  1.5 4.3  1.6 0.16
Outcome measures
Binary restenosis >50% 7/25 (28) 11/19 (57.9) 0.0457
Positive remodelling, late
lumen loss <0 mm
0/25 (0) 3/19 (15.8) 0.07
Target lesion
revascularization
2/26 (7.7) 3/22 (13.6) 0.65
Rutherford class at
6 months
1 (1, 2.75) 1 (1, 3.5) 0.87
Values are mean  SD, n/n (%), or median (interquartile range).RESULTS
Within 14 months, 50 patients were randomized (1:1)
to PCB or DES treatment of long infrapopliteal lesions.
The ﬂow of the study is shown in the chart of
Figure 1. Baseline demographical variables were
equally distributed between the 2 groups with the
sole exception of age (75.3  8.0 years in DES vs.
67.6  11.3 years in PCB, p ¼ 0.03) (Table 2). In total,
on an ITT analysis, 52 limbs (PCB group: n ¼ 25, DES
group: n ¼ 27) and 55 vessels (PCB group: n ¼ 25,
DES group: n ¼ 30) were randomized. Lesion length
was slightly higher in the PCB group (148  56.7 mm
vs. 127  46.5 mm in the DES group; p ¼ 0.14),
whereas chronic total occlusions (CTO) at baseline
were numerically more in the DES group (7 of 30 vs.
3 of 25 in the PCB group; p ¼ 0.31). The subintimal
approach was used in 6 of 7 occlusions treated in theDES group and in 3 of 3 occlusions in the PCB group
(6 of 30 vs. 3 of 25 lesions; p ¼ 0.49). Retrograde
pedal access was not applied in any case. Baseline
demographics and morphological characteristics of
all lesions treated are reported in detail in Table 2. In
1 case, the angioplasty result after PCB treatment
was suboptimal (ﬂow-limiting dissection) and the
patient crossed over to treatment with DES. Hence,
technical success was 24 of 25 (96%) in the PCB
FIGURE 2 Paired QVA Analysis
Paired analysis of the immediate and 6-month angiographic outcomes in the
PCB- and DES-treated lesions. Immediate post-procedure residual stenosis
was signiﬁcantly higher in the PCB group, but it was similar between both
groups at 6 months. Note that positive remodeling with regression of the
stenosis and negative late lumen loss was noted in a few PCB cases; however,
binary restenosis was signiﬁcantly higher in the PCB group than in the DES
group. QVA ¼ quantitative vessel analysis; other abbreviations as in Figure 1.
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1052group and 25 of 25 (100%) in the DES group. Imme-
diate residual post-procedure stenosis was signiﬁ-
cantly lower in DES (9.6  2.2% vs. 24.8  3.5% in
PCB; p < 0.0001). Three (3 of 25) and 1 (1 of 25)3 QVA 6-Month Outcomes
diagrams demonstrate late lumen loss results and total length of the
ed vascular segment (binary restenosis; >50%) at the 6-month
p angiogram. Crosses and horizontal lines denote the mean and
values, respectively. There was no signiﬁcant difference between the
s in either case. Abbreviations as in Figures 1 and 2.patients were lost to follow-up from the PCB and the
DES groups, respectively (p ¼ 0.61). There were 2
deaths (2 of 25) after PCB and 3 after DES treatment
(3 of 25; p ¼ 1.00). All deaths were attributed to
cardiovascular events because of underlying comor-
bidities. One limb was amputated in the PCB group
(1 of 25) and 2 in the DES group (2 of 27; p ¼ 1.00)
(Table 3).
In total, 44 angiograms were evaluable with QVA
at 6 months (Figure 2). Total vessel reocclusion
occurred in 3 of 19 (15.8%) of the treated lesions in
the PCB group versus 5 of 25 (20.0%) in the DES
group (p ¼ 0.72). Although stent thrombosis could
not be veriﬁed in any of the cases, it was strongly
suspected in the 2 cases of limb amputation occur-
ring in the DES group 2 months after the procedure.
Events of target lesion >50% angiographic reste-
nosis were signiﬁcantly fewer in the DES group (7 of
25 [28%)] vs. 11 of 19 [57.9%] in PCB; p ¼ 0.0457)
(Table 3). LLL at 6 months was similar in both
groups (1.35  0.2 mm in DES vs. 1.15  0.3 mm in
PCB; p ¼ 0.62) (Figure 3). Positive vessel wall
remodeling was observed in 3 cases in the PCB arm
(3 of 19 [15.8%] vs. 0 of 19 [0%] in DES; p ¼ 0.07).
The length of the restenosed vessel segment was
slightly lower in DES, but not signiﬁcantly so (3.6 
1.5 cm vs. 4.3  1.6 cm; p ¼ 0.16) (Figure 3). There
were no signiﬁcant differences with regard to TLR
(2 of 26 [7.7%] in DES vs. 3 of 22 [13.6%] in PCB; p ¼
0.65) and Rutherford class at 6 months (median:
stage 1 [IQR: 1 to 2.75] in DES vs. 1 [IQR: 1 to 3.5] in
PCB; p ¼ 0.87) (Figure 4). Similar counts of com-
plete, partial, and unchanged wound healing were
observed in both groups after 6 months (Figure 5).
Examples of follow-up angiograms in both the DES
and PCB study arms are shown in Figures 6 and 7,
respectively. During angiographic follow-up, no
stent fractures were detected in the DES group.
Finally, no procedure-related minor or major
complication was noted.
DISCUSSION
Endovascular treatment of below-the-knee arterial
occlusive disease is increasingly proposed as the
method of choice for revascularization of the crural
arteries, especially in patients suffering from CLI
(1–3). Although DES have established their superior-
ity over plain balloon angioplasty and bare-metal
stents for the treatment of short infrapopliteal le-
sions (13), there is no strong evidence to support
their use in longer lesions (21). Below-the-knee
application of DES has been also hampered by cost
issues because with current devices (the longest
FIGURE 4 Clinical Outcomes
Box plot diagrams demonstrate the Rutherford stage classiﬁcation at baseline
and 6 months in both groups. Crosses and horizontal lines denote the
mean and median values, respectively. There was no statistically signiﬁcant
difference in Rutherford stage at baseline (Table 2) or at 6 months (Table 3).
Abbreviations as in Figure 1.
FIGURE 5 Wound Healing Outcomes
Stacked box plots of complete, partial, or unchanged wound healing in case of
tissue loss at baseline. Results are shown as the actual counts of events.
Abbreviations as in Figure 1.
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1053available is 38 mm) multiple overlapping stents
would be necessary for full coverage of any lesion
>10 cm, raising procedural costs (22). In addition,
the expected increased difﬁculty to cross an
occluded stent compared with a reoccluded native
lesion previously treated with balloon angioplasty
could be another factor to take into consideration
during decision making for long infrapopliteal le-
sions. On the other hand, application of PCB devices
has been received enthusiastically in the femo-
ropopliteal arteries, and recently, promising results
have also been shown in the below-the-knee arena
(15–18).
The IDEAS trial is the ﬁrst study to directly
compare head-to-head the use of DES versus PCB for
the treatment of long infrapopliteal lesions that
typically characterize most cases of tibial revascu-
larization. The study was designed to compare the
2 most commonly used local drug delivery technol-
ogies for endovascular treatment. The purpose of
both technologies is the inhibition of restenosis and
thereby reduction of repeat angioplasty and
improvement of clinical outcomes. Hence, the trial
was powered on the basis of an equivalence hy-
pothesis, and angiographic restenosis >50% was set
as the primary endpoint in order to compare NIH
inhibition.
The IDEAS study has shown that infrapopliteal use
of PCB, compared with DES, was associated with sta-
tistically signiﬁcantly higher binary vascular reste-
nosis at the 6-month time point. Of note, technical
success was very high in both groups with only 1
crossover from the PCB to the DES group, albeit a
small number of CTO were treated. CTO are theoreti-
cally more prone to require bailout stenting because of
a suboptimal angioplasty result. Not surprisingly,
immediate post-procedure residual stenosis was
signiﬁcantly higher after PCB use (more than
double than with DES), which is not an unexpected
ﬁnding as there is no permanent vascular scaffolding
like there is in the case of metal stenting. It could be
argued therefore that this “handicap” at the beginning
of the study after completion of the index procedure
may have partly contributed to the higher vessel
restenosis noted in the cases of the PCB treated
lesions.
We further investigated the morphology and
pattern of NIH by analyzing the LLL and length of
restenosed vascular segment as quantitative surro-
gate markers of the extent of vascular restenosis.
Length was slightly higher but not signiﬁcantly so in
the PCB group. On the other hand, QVA showed the
paradox that binary restenosis was signiﬁcantly
lower in DES, but LLL was numerically lower incases of PCB. However, this may be explained by
the positive vessel wall remodeling (negative LLL)
that was identiﬁed in 3 PCB cases (3 of 19; 15.8%)
and may have counteracted in part the increased
post-procedure stenosis of PCB at baseline. Of note,
positive remodeling has been described also after
DES implantation in the coronary arteries, where it
FIGURE 6 Example Follow-Up Angiograms in the DES Group
Two different examples of 6-month follow-up angiograms after
full metal drug-eluting stent (DES) jacket of (A) the whole
anterior tibial artery and (B) the tibioperoneal artery for critical
limb ischemia treatment. Note the widely patent vessels without
any signiﬁcant restenosis throughout the stented vessel
segments at 6 months.
FIGURE 7 Example Follow-Up Angiograms in the PCB Group
Examples of (A) immediate baseline post-procedure image and
(B) 6-month follow-up angiogram following paclitaxel-coated
balloon (PCB) treatment of the proximal and middle third of the
anterior tibial artery in a patient with critical limb ischemia. Note
the development of signiﬁcant multilevel focal restenosis
(>50%) at 6 months.
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1054was associated with aneurysmal degeneration and
stent malapposition (23). It has also been reported
after PCB use in the superﬁcial femoral artery
with the hypothesis of plaque regression at 6
months (24).
Furthermore, the reported difference of binary
restenosis did not translate into any signiﬁcant dif-
ferences in the secondary clinical outcome measures.
Similar improvement in the Rutherford classes and
wound healing progression was noted in both study
arms, and as those patients were mainly CLI cases,
mortality and amputation rates were within the ex-
pected range (1). It is evident though that the trial
was not adequately powered to detect any such
differences.
The signiﬁcantly lower rate of restenosis found in
the case of DES in the IDEAS study is in line withpreviously published cohort and randomized trials
that included a variety of lesion lengths and follow-
up periods (13,21). On the other hand, there was
some discrepancy in the results of PCB compared
with those of previously published studies. In a
cohort of 109 CLI limbs (mean lesion length: 17 cm),
Schmidt et al. (16) reported a restenosis rate of
nearly 30% at 3 months (84 lesions analyzed) with
>90% clinical improvement and around 75%
complete wound healing at 1 year. Liistro et al.
(18) performed a randomized comparison (the
DEBATE-BTK [Drug-Eluting Balloon in Peripheral
Intervention for Below the Knee Angioplasty Evalu-
ation] trial) of PCB versus plain balloon angioplasty
in 132 patients with 158 infrapopliteal lesions (>4
cm). The investigators recently reported a striking
reduction of angiographic restenosis in the PCB
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1055group with a rate of 27% versus 74% in the control
group after 1 year (p < 0.001). Only 1 major ampu-
tation was reported out of 132 CLI patients corre-
sponding to a limb salvage rate of nearly 100% in
both groups (18).
STUDY LIMITATIONS. The scientiﬁc evidence amassed
and reported by the IDEAS randomized trial
suffers from certain limitations. First, this was a
single-center study and a relatively small number of
patients with a low rate of CTO were recruited. Sec-
ond, overall follow-up was limited to 6 months when
a digital angiogram was performed for QVA purposes.
In addition, there was an absence of an independent
core lab for the QVA analysis, but there was no
commercial sponsor or other source of funding. The
study was designed as an exploratory study for
equivalence between DES and PCB and was appro-
priately powered only for the outcome of restenosis
in order to compare NIH between the 2 treatments.Hence, robust conclusions on long-term efﬁcacy and
clinical outcomes cannot be derived.
CONCLUSIONS
DES are related with signiﬁcantly better immediate
residual post-procedure stenosis and lower vessel
restenosis than PCB are when used in long infrapopli-
teal lesions. PCB may produce positive vessel re-
modeling. Larger scale multicenter trials are needed
to verify these results and to investigate further
whether thisﬁndingmay translate to improved clinical
outcomes.
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